文献速递乳房整形与再造

即刻假体乳房再造术后围手术期与延长抗生素预防疗程的评价

Evaluation of Perioperative Versus Extended Courses of Antibiotic Prophylaxis After Immediate Implant-Based Breast Reconstruction.
PubMed 文献 · Ann Plast Surg · 2023-02-15

单机构回顾性研究纳入2018年6月至2020年4月间169例(285侧)即刻假体乳房再造患者,比较围手术期24小时抗生素与≥7天延长抗生素对手术部位感染的预防效果。结果显示两组感染率、再造失败率和血清肿率无显著差异,但仅接受围手术期抗生素且BMI≥25的患者感染率显著更高。

要点

  • 围手术期24小时与≥7天抗生素预防的感染率无显著差异(P=0.273)。
  • 仅用围手术期抗生素的BMI≥25患者感染率显著高于BMI<25者(25.6% vs 7.1%,P=0.050)。
  • 作者认为选择预防方案时应考虑BMI。

核心结论

  • 围手术期与延长抗生素预防的感染率无统计学差异,提示当前预防方案疗效大致相似,方案选择基于外科医生偏好和患者个体化考量。
  • 仅接受围手术期预防且超重的患者感染率显著更高,提示选择预防方案时应考虑BMI。

研究设计与样本

  • 单机构回顾性研究,纳入2018年6月至2020年4月期间接受即刻假体乳房再造的患者。
  • 共169例患者(285侧乳房),根据抗生素预防方案分为组1(围手术期24小时抗生素)和组2(≥7天抗生素)。
  • 使用SPSS v26.0进行统计分析,P≤0.05认为有统计学意义。

主要发现

  • 平均年龄52.4±10.2岁,平均BMI 26.8±5.7 kg/m2。
  • 25.6%患者行保留乳头乳房切除术,69.1%行保留皮肤乳房切除术,5.3%行全乳房切除术。
  • 假体置于胸肌前、胸肌后和双平面者分别占16.7%、19.2%和64.1%,78.7%的病例使用脱细胞真皮基质。
  • 42.0%患者接受24小时预防(组1),58.0%接受延长预防(组2);共识别25例感染(14.8%),其中9例(5.3%)导致再造失败。
  • 双变量分析中,两组感染率(P=0.273)、再造失败率(P=0.653)和血清肿率(P=0.125)无显著差异,血肿率有差异(P=0.046)。

临床怎么用

  • 作者认为围手术期与延长抗生素预防的疗效大致相似,方案选择可基于外科医生偏好和患者个体化考量。
  • 作者建议选择预防方案时应考虑BMI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immediate implant-based breast reconstruction (IIBR) is the most commonly used method in breast reconstruction in the United States. However, postoperative surgical site infections (SSIs) can cause devastating reconstructive failure. This study evaluates the use of perioperative versus extended courses of antibiotic prophylaxis after IIBR for the prevention of SSI. METHODS: This is a single-institution retrospective study of patients who underwent IIBR between June 2018 and April 2020. Detailed demographic and clinical information was collected. Patients were divided into subgroups based on antibiotic prophylaxis regimen: group 1 consisted of patients who received 24 hours of perioperative antibiotics and group 2 consisted of patients who received ≥7 days of antibiotics. Statistical analyses were conducted using SPSSv26.0 with P ≤ 0.05 considered statistically significant. RESULTS: A total of 169 patients (285 breasts) who underwent IIBR were included. The mean age was 52.4 ± 10.2 years, and the mean body mass index (BMI) was 26.8 ± 5.7 kg/m2. Twenty-five percent of patients (25.6%) underwent nipple-sparing mastectomy, 69.1% skin-sparing mastectomy, and 5.3% total mastectomy. The implant was placed in the prepectoral, subpectoral, and dual planes in 16.7%, 19.2%, and 64.1% cases, respectively. Acellular dermal matrix was used in 78.7% of cases. A total of 42.0% of patients received 24-hour prophylaxis (group 1), and 58.0% of patients received extended prophylaxis (group 2). Twenty-five infections (14.8%) were identified, of which 9 (5.3%) resulted in reconstructive failure. In bivariate analyses, no significant difference was found between groups in rates of infection (P = 0.273), reconstructive failure (P = 0.653), and seroma (P = 0.125). There was a difference in hematoma rates between groups (P = 0.046). Interestingly, in patients who received only perioperative antibiotics, infection rates were significantly higher in those with BMI ≥ 25 (25.6% vs 7.1%, P = 0.050). There was no difference in overweight patients who received extended antibiotics (16.4% vs 7.0%, P = 0.160). CONCLUSIONS: Our data demonstrate no statistical difference in infection rates between perioperative and extended antibiotics. This suggests that the efficacies of current prophylaxis regimens are largely similar, with choice of regimen based on surgeon preference and patient-specific considerations. Infection rates in patients who received perioperative prophylaxis and were overweight were significantly higher, suggesting that BMI should be taken into consideration when choosing a prophylaxis regimen.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Zhang C, Moroni EA, Bustos SS, et al. Evaluation of Perioperative Versus Extended Courses of Antibiotic Prophylaxis After Immediate Implant-Based Breast Reconstruction. Ann Plast Surg. 2023. PMID: 37399483. doi:10.1097/SAP.0000000000003473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。